Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stem Cells and Tissue EngineeringPeritransplant Blood Component Therapy

Stem Cells and Tissue Engineering: Peritransplant Blood Component Therapy [The clinical use of blood components (transfusion therapy) is an efficient method for the support of patients who underwent autologous or HLA-matched allogeneic hematopoietic SC transplant following chemotherapy (and nowadays just rarely total body irradiation—TBI) conditioning regimens. Thus, clinical qualification of blood replacement, as well as a variety of alternatives to “traditional” blood component support (autologous transfusions, blood substitutes, hematopoietic cytokines—growth factors), make the specific elements of current peritransplant transfusion therapy. The basic aim of transfusion therapy is the reconstitution of blood homeostasis through the improvement of red blood cell (RBC), platelet, white blood cell (WBC), or rarely coagulation factor deficiencies by replacement and/or stimulation of their production using cytokines. The events affecting the features of transfusion therapy are: (a) category and severity of patient’s hematological deficit, and (b) type and quantity of blood component(s) or cytokine needed. These factors have to be determined before the initiation of blood replacement in all situations, and it is the highest priority in a high-quality transfusion therapy [1–3].] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Stem Cells and Tissue EngineeringPeritransplant Blood Component Therapy

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/stem-cells-and-tissue-engineering-peritransplant-blood-component-KE70GCqfFS

References (33)

Publisher
Springer New York
Copyright
© The Author(s) 2013
ISBN
978-1-4614-5504-2
Pages
61 –67
DOI
10.1007/978-1-4614-5505-9_11
Publisher site
See Chapter on Publisher Site

Abstract

[The clinical use of blood components (transfusion therapy) is an efficient method for the support of patients who underwent autologous or HLA-matched allogeneic hematopoietic SC transplant following chemotherapy (and nowadays just rarely total body irradiation—TBI) conditioning regimens. Thus, clinical qualification of blood replacement, as well as a variety of alternatives to “traditional” blood component support (autologous transfusions, blood substitutes, hematopoietic cytokines—growth factors), make the specific elements of current peritransplant transfusion therapy. The basic aim of transfusion therapy is the reconstitution of blood homeostasis through the improvement of red blood cell (RBC), platelet, white blood cell (WBC), or rarely coagulation factor deficiencies by replacement and/or stimulation of their production using cytokines. The events affecting the features of transfusion therapy are: (a) category and severity of patient’s hematological deficit, and (b) type and quantity of blood component(s) or cytokine needed. These factors have to be determined before the initiation of blood replacement in all situations, and it is the highest priority in a high-quality transfusion therapy [1–3].]

Published: Oct 1, 2012

Keywords: Fresh Freeze Plasma; Transfusion Practice; Transfusion Therapy; Blood Replacement; Transfusion Trigger

There are no references for this article.